Vogenx (VOGX) investor relations material

Executive summary

• Clinical-stage drug developer focused on metabolic and gastrointestinal diseases, with lead candidate mizagliflozin targeting PBH, gastroparesis, and GIP-induced Cushing's Syndrome.

• No commercial products or product revenue to date; operations have centered on R&D, business planning, and capital raising.

• Completed IPO in August 2026, raising $84.9 million in net proceeds.

Financial highlights

• Net loss for Q2 2026 was $384,430, compared to $294,797 in Q2 2025.

• Net loss for the six months ended June 30, 2026 was $859,882, up from $651,416 for the same period in 2025.

• Operating expenses for Q2 2026 totaled $355,384, up from $310,660 in Q2 2025, driven by higher R&D and G&A costs.

• Cash and cash equivalents as of June 30, 2026 were $193,017, prior to IPO proceeds.

• Accumulated deficit reached $11.7 million as of June 30, 2026.

Outlook and guidance

• Management expects operating losses and expenses to increase as clinical programs advance and public company costs rise.

• IPO proceeds, combined with existing cash, are expected to fund operations for at least 12 months from the financial statement issuance date.

• Additional capital will be required before commencing Phase 3 trials.